Clinical Trial Update: An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037 [EARLY_Phase 1]

View source ↗

Summary

An early-phase exploratory open-label study of the radiotracer [F-18]VM4-037 across multiple cancer indications has completed; sponsor is Siemens Molecular Imag…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Hepatocellular Carcinoma
• Lung Cancer
• Renal Cell Carcinoma

Drugs mentioned

• [F-18]VM4-037 (VM4-037 (radiotracer))

Snippet

Sponsor: Siemens Molecular Imaging | Conditions: Lung Cancer, Squamous Cell Carcinoma | EARLY_Phase 1 | Status: COMPLETED